Abstract The present study was undertaken to determine the anticancer efficacy of zerumbone (ZER), a sesquiterpene from subtropical ginger, against human breast cancer cells in vitro and in vivo. ZER treatment caused a dosedependent decrease in viability of MCF-7 and MDA-MB-231 human breast cancer cells in association with G 2 /M phase cell cycle arrest and apoptosis induction. ZERmediated cell cycle arrest was associated with downregulation of cyclin B1, cyclin-dependent kinase 1, Cdc25C, and Cdc25B. Even though ZER treatment caused stabilization of p53 and induction of PUMA, these proteins were dispensable for ZER-induced cell cycle arrest and/or apoptosis. Exposure of MDA-MB-231 and MCF-7 cells to ZER resulted in downregulation of Bcl-2 but its ectopic expression failed to confer protection against ZER-induced apoptosis. On the other hand, the SV40 immortalized mouse embryonic fibroblasts derived from Bax and Bak double knockout mice were significantly more resistant to ZER-induced apoptosis. ZER-treated MDA-MB-231 and MCF-7 cells exhibited a robust activation of both Bax and Bak. In vivo growth of orthotopic MDA-MB-231 xenografts was significantly retarded by ZER administration in association with apoptosis induction and suppression of cell proliferation (Ki-67 expression). These results indicate that ZER causes G 2 /M phase cell cycle arrest and Bax/Bakmediated apoptosis in human breast cancer cells, and retards growth of MDA-MB-231 xenografts in vivo.
Introduction
Breast cancer is a major health problem for women worldwide [1] necessitating identification of novel anticancer strategies. Merit of this objective is further enforced as many of the known risk factors associated with breast cancer are not easily modifiable (e.g., genetic predisposition) [2, 3] . Dietary compounds owing to their safety have drawn considerable attention in recent years for the discovery of novel cancer preventive and therapeutic agents [4] . Bioactive compounds with preventive efficacy against cancer in preclinical rodent models have now been identified from many edible vegetables, including cruciferous vegetables (e.g., watercress and broccoli) and garlic [4] [5] [6] [7] [8] . Moreover, population-based case-control studies continue to support the notion that dietary intake of certain fruits and vegetables may reduce the risk of cancer [9] [10] [11] .
Zerumbone (2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one; hereafter abbreviated as ZER), a monocyclic sesquiterpene derived from tropical ginger Zingiber zerumbet, is one such phytochemical with preventive efficacy in preclinical rodent models of cancer and pancreatitis [12] [13] [14] [15] [16] [17] . For example, dietary administration of ZER for 5 weeks caused reduction in the frequency of aberrant crypt foci in association with suppression of cyclooxygenase-2 [12] . Oral feeding of ZER inhibited dextran sodium sulfate-induced colitis in female ICR mice [13] . ZER treatment was also reported to suppress skin tumor initiation and promotion in ICR mice [14] . ZER administration caused regression of cervical intraepithelial neoplasia in female Balb/c mice prenatally exposed to diethylstilboestrol [18] . Diethylnitrosamine-initiated and 2-acetylaminofluorene-promoted liver carcinogenesis was inhibited by treatment with ZER [19] .
Cell culture models have also been used to study anticancer effects of ZER [20] [21] [22] [23] [24] [25] [26] . For example, ZER inhibited proliferation of human colonic adenocarcinoma cell lines in association with dysfunction of mitochondria transmembrane leading to apoptotic cell death [20] . Cytotoxic effect of ZER on leukemia cells was found to be mediated through cell cycle arrest and Fas-and mitochondria-mediated apoptosis [21] . In liver cancer HepG2 cells, ZERinduced apoptosis was shown to be independent of p53 but associated with modulation of Bax/Bcl-2 ratio [22] . Despite these advances, however, the mechanisms underlying growth inhibitory and proapoptotic effect of ZER are not fully understood. In the present study, we have addressed this mechanistic gap using MDA-MB-231 (an estrogen-independent cell line with mutant p53) and MCF-7 (an estrogen responsive cell line with wild-type p53) human breast cancer cells as a model.
Materials and methods

Reagents
ZER was either purified as described previously [27] or purchased from Sigma-Aldrich (St. Louis, MO). Reagents including 4 0 ,6-diamidino-2-phenylindole (DAPI) and propidium iodide (PI) were from Sigma-Aldrich, whereas cell culture reagents were purchased from Invitrogen-Life Technologies (Carlsbad, CA). Sources of antibodies were as follows: antibodies against Cdc25C, cleaved poly-(ADP-ribose)-polymerase (PARP), and p53 were from Cell Signaling Technology (Danvers, MA); anti-cyclin B1, anticyclin-dependent kinase 1 (Cdk1), anti-Bak, anti-Bax, and anti-p53 upregulated mediator of apoptosis (PUMA) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA); antibodies against Cdc25B and active Bax (for immunofluorescence microscopy) were purchased from BD Biosciences (San Diego, CA); anti-Bcl-2 antibody was from Dako-Agilent Technologies (Houston, TX); an antibody specific for detection of active Bak (for immunofluorescence microscopy) was from Calbiochem (Billerica, MA); and anti-actin antibody was from Sigma-Aldrich. MitoTracker Green and Alexa Fluor 568-conjugated goat anti-mouse antibodies were from Invitrogen-Life Technologies. Annexin V-FITC/PI Apoptosis Detection kit was purchased from BD Biosciences. The p53-targeted small interfering RNA (siRNA) was purchased from Santa Cruz Biotechnology, whereas a control nonspecific siRNA was purchased from Qiagen (Germantown, MD).
Cell lines, cell survival assay, and analysis of cell cycle distribution MDA-MB-231, MCF-7, and MCF-10A cells were purchased from American Type Culture Collection (Manassas, VA) and maintained, as described by us previously [28] . Wild-type HCT-116 cell line and its isogenic PUMA knockout (KO) variant were generously provided by Dr. Bert Vogelstein (Johns Hopkins University, Baltimore, MD) and cultured in McCoy's 5A modified medium supplemented with 10 % fetal bovine serum and antibiotics. Mouse embryonic fibroblasts (MEF) derived from wildtype (WT) and Bax and Bak double knockout (DKO) mice and immortalized by transfection with a plasmid containing SV40 genomic DNA were generously provided by the late Dr. Stanley J. Korsmeyer (Dana-Farber Cancer Institute, Boston, MA) and maintained, as described previously [29] . Stock solution of ZER was prepared in dimethyl sulfoxide (DMSO), and diluted with complete media before use. An equal volume of DMSO (final concentration 0.1 %) was added to controls. Effect of ZER treatment on cell survival was determined by trypan blue dye exclusion assay, as described by us previously [30] or cell proliferation assay using a Cell Proliferation Assay kit (Promega, Madison, WI) according to the manufacturer's instructions. Effect of ZER treatment on cell cycle distribution was determined by flow cytometry after staining the cells with PI, as described by us previously [31] .
Western blotting
Control and ZER-treated cells were processed for immunoblotting, as described by us previously [28] [29] [30] [31] [32] .
Densitometric quantitation was done using UN-SCAN-IT software version 5.1 (Silk Scientific Corporation, Orem, UT).
Apoptosis assays
Apoptosis induction was assessed by quantitation of histone-associated DNA fragment release into the cytosol using an ELISA kit from Roche Applied Sciences (Indianapolis, IN) or flow cytometry using Annexin V-FITC/PI Apoptosis Detection kit.
RNA interference MCF-7 (1.5 9 10 5 ) cells were seeded in six-well plates and transfected at *50 % confluency with 100 nM of p53-targeted siRNA or control siRNA using oligofectamine. Twenty-four hours after transfection, the cells were treated with DMSO (control) or ZER (20 lM) for 24 h. Cells were collected and processed for western blotting and determination of cell cycle distribution.
Ectopic expression of Bcl-2 by transient transfection MDA-MB-231 and MCF-7 cells were transiently transfected at *50-60 % confluency with the empty pSFFVneo vector or pSFFV vector encoding for Bcl-2 using Fu-GENE6 transfection reagent. Twenty-four hours after transfection, the cells were treated with DMSO or ZER and processed for immunoblotting and measurement of apoptosis and cell viability.
Measurement of mitochondrial membrane potential
Effect of ZER on mitochondrial membrane potential was measured using potential-sensitive dye JC-1 ( 6 cells was injected orthotopically in both inguinal mammary fat pads. On the same day, the mice began intraperitoneal administration of either PBS (100 lL) or ZER (0.18 or 0.35 mg ZER/mouse; equates to about 7.5 and 15.7 mg ZER/kg body weight, respectively, in 100 lL PBS) five times/week (Monday through Friday). At the onset of the study, there were 10 mice in each group. Number of effective mice at the conclusion of the study was n = 6 for the control group and 0.18 mg ZER/mouse groups and n = 7 for the 0.35 mg ZER/mouse group because of premature deaths unrelated to treatment and/or failure of tumor take. In the 0.35 mg ZER/mouse group, tumor grew only on one flank in two mice. Body weights of the mice were recorded weekly.
Detection of apoptotic bodies by TUNEL assay and immunohistochemistry for Ki-67
A portion of the tumor tissue was fixed in 10 % neutralbuffered formalin, dehydrated, embedded in paraffin, and sectioned at 4-5 lm thickness. TUNEL staining and immunohistochemical analysis for Ki-67 expression was performed as described by us previously [5] [6] [7] [8] .
Results
ZER inhibited viability of cultured human breast cancer cells by causing growth arrest
Structure of ZER is shown in Fig. 1a . Viability of MDA-MB-231 and MCF-7 cells was decreased significantly upon treatment with ZER in a concentration-and time-dependent manner as evidenced by trypan blue dye exclusion assay (Fig. 1b) and cell proliferation assay (results not shown). For example, the IC 50 for ZER in MDA-MB-231 cells after 24 and 48 h exposure was 9.9 ± 4.9 lM and 4.2 ± 1.2 lM (n = 3), respectively. The IC 50 for ZER in MCF-7 cells after 24 and 48 h treatment was 10.1 ± 5.3 and 2.9 ± 0.8 lM (n = 3), respectively. Exposure of MDA-MB-231 ( with DMSO-treated control by one-way ANOVA followed by Dunnett's test. d Immunoblotting for cyclin B1, Cdk1, Cdc25C, and Cdc25B using lysates from MDA-MB-231 and MCF-7 cells treated with DMSO or the indicated concentrations of ZER. The blots were re-probed with anti-actin antibody as a loading control. Numbers on top of the immunoreactive bands represent changes in protein levels relative to corresponding DMSO-treated control. Each experiment was performed at least twice and the results were consistent protein levels of cyclin B1, Cdk1, Cdc25C, and Cdc25B in both MDA-MB-231 and MCF-7 cells (Fig. 1d) .
ZER caused apoptosis in human breast cancer cells (Fig. 2b) . Consistent with these results, the ZER-treated MDA-MB-231 and MCF-7 cells (24 h treatment) exhibited a dosedependent and statistically significant increase in histoneassociated DNA fragment release into the cytosol compared with corresponding DMSO-treated controls (Fig. 2c) . Finally, apoptosis induction by ZER in MDA-MB-231 and MCF-7 cells was confirmed by immunoblotting for cleaved PARP (Fig. 2d) . In contrast to MDA-MB-231 and MCF-7 cells, ZER treatment (5-50 lM for 24 h) failed to induce histone-associated DNA fragment release into the cytosol in MCF-10A cells (data not shown). Collectively, these results indicated that breast cancer cells were more sensitive to ZER-mediated apoptosis compared with normal cells.
The p53 and PUMA proteins were dispensable for ZER-induced apoptosis PUMA is a BH3-only member of the Bcl-2 family of proapoptotic proteins that facilitates apoptosis by different stimuli [34] . There was a marked increase in the levels of PUMA protein after treatment with ZER in both MDA-MB-231 and MCF-7 cells (Fig. 3a) . Because PUMA is a p53-regulated protein, these results indicated that PUMA induction resulting from ZER treatment involved p53-independent mechanism(s). However, PUMA was dispensable for ZER-mediated apoptosis induction (Fig. 3b) as well as inhibition of cell proliferation (Fig. 3c ) as evidenced by analysis in wild-type and PUMA KO variants of HCT-116 cells. Likewise, even though ZER treatment resulted in stabilization of p53 protein in MCF-7 cells (Fig. 3d) , the ZER-induced enrichment of sub-diploid apoptotic fraction (Fig. 3e) as well as G 2 /M fraction ( Fig. 3f ) was sustained even after knockdown of the p53 protein by 60 %. Based on these observations, we conclude that both p53 and PUMA proteins are dispensable for cellular responses to ZER.
Bcl-2 overexpression failed to confer protection against ZER-induced apoptosis
Because ZER was previously shown to modulate levels of Bcl-2 protein in liver cancer cells [22] , we determined its role in breast cancer cell apoptosis by ZER. As can be seen in Fig. 4a (Fig. 4b) . However, ectopic expression of Bcl-2 failed to abolish ZER-mediated cleavage of PARP (Fig. 4b) , histone-associated DNA fragment release into the cytosol (Fig. 4c) or inhibition of cell survival (Fig. 4d) . Even though % survival upon treatment with ZER in vector-transfected control MDA-MB-231 cells appeared different from that in Bcl-2 overexpressing cells, the difference was not significant in any of the 3 independent experiments (Fig. 3d) .
ZER-induced apoptosis was mediated by activation of Bax and Bak
We next studied potential involvement of multidomain proapoptotic proteins Bax and Bak in ZER-induced apoptosis. The protein levels of Bax and Bak were only modestly increased upon treatment of MDA-MB-231 and MCF-7 cells with ZER (Fig. 5a ). Many apoptogenic signals promote conformational change (activation) of Bax and Bak which in turn causes their oligomerization to induce pores in the outer membrane resulting in a loss of the mitochondrial membrane potential followed by cell death [35, 36] . As shown in Fig. 5b , ZER treatment caused collapse of mitochondrial membrane potential as evidenced by accumulation of monomeric JC-1 (green fluorescence). We performed immunocytochemistry to determine activation of Bax and Bak in cells treated with 20 lM of ZER (8 h) using antibodies specific for detection of active Bax (6A7; BD Biosciences) and active Bak (AM03; Calbiochem). The ZER treatment caused activation of Bax and Bak in both MDA-MB-231 and MCF-7 cells as evidenced by merging of the Bax-or Bak-associated red fluorescence and MitoTracker Green-associated fluorescence leading to appearance of yellow-orange color, which was rare in DMSO-treated control cells (Fig. 6a) . The ZER-treated MDA-MB-231 and MCF-7 cells also showed change in the appearance of mitochondrial network, as mitochondria that normally have an elongated structure acquired a rounded shape with closely packed stacks (Fig. 6a) .
Contribution of Bax and Bak in apoptotic response to ZER was confirmed by comparing sensitivities of SV40 immortalized MEF derived from WT and DKO (Bax and Bak double knockout) mice. The ZER treatment (20 or 40 lM for 24 or 48 h) caused a dose-dependent increase in the apoptotic cells in both WT and DKO MEF, but the apoptosis was significantly more pronounced in the WT MEF than in the DKO (Fig. 6b,c) . Collectively, these results indicated that: (a) ZER treatment caused activation of both Bax and Bak, and (b) Bax and Bak deficiency conferred significant protection against ZER-induced apoptosis in immortalized MEF. The WT and DKO MEF is a better cellular model to test the role of Bax and Bak over RNA interference which often fails to produce complete knockdown if simultaneously attempted for more than one protein. We determined the effect of ZER administration on growth of MDA-MB-231 cells implanted orthotopically in mammary fat pads of female SCID mice. The ZER concentrations used in the present study were within the range utilized in previous animal studies [18, 19] . The initial and final body weights of the control and ZER-treated mice did not differ significantly (Fig. 7a) . In this experiment, luciferase expressing MDA-MB-231 (clone Luc D3H1) cells were used with the intention to image the mice as well as to quantify bioluminescence. However, this was not possible because the number of effective mice was smaller than initially planned and due to variability inherent to bioluminescence (results not shown). Nevertheless, the average wet weight of the tumor after sacrifice of the animals was significantly lower in the 0.18 mg ZER/mouse group compared with control group (Fig. 7b) . The difference between the control group and the 0.35 mg ZER/mouse group did not reach statistical significance due to large data scatter in the later. Nevertheless, these results demonstrated in vivo efficacy of ZER against MDA-MB-231 xenografts.
ZER administration increased apoptosis and inhibited cell proliferation in the MDA-MB-231 tumor xenografts ZER administration resulted in a statistically significant increase in number of apoptotic bodies in the tumor as visualized by TUNEL assay (Fig. 7c) . In addition, expression of proliferation marker Ki-67 [37] was significantly lower in the tumors of ZER-treated mice compared with those of control mice, and the difference was significant at the 0.35 mg ZER/mouse group (Fig. 7d) .
Discussion
Results presented herein indicate that ZER treatment inhibits survival of human breast cancer cells regardless of the estrogen responsiveness or the p53 status. Growth inhibitory effect of ZER is associated with cell cycle arrest and apoptosis induction. Activity of ZER against breast cancer is not restricted to cultured cells as growth of MDA-MB-231 xenografts in vivo is significantly retarded by ZER administration. Consistent with cellular data, antitumor effect of ZER in vivo is accompanied by reduced cell proliferation as evidenced by Ki-67 expression and increased apoptosis. Moreover, ZER administration is well tolerated by the mice and does not cause weight loss or any other side effects. Prevention of induced cancers in rodents by ZER has been documented previously [12, 14, 16] , but the present study is the first published report showing in vivo efficacy of this compound against transplanted breast cancer cells. These observations provide impetus for future in vivo evaluation of ZER for prevention of mammary cancer in preclinical models to justify its clinical investigation as a chemopreventive agent. In this context, it is important to mention that addition of a different variety of ginger (Z officinale) (1.5 g/d in three divided doses every 8 h) to standard antiemetic therapy (granisetron plus dexamethasone) in patients with advanced breast cancer effectively reduces the prevalence of chemotherapy-induced nausea and vomiting [38] . In a phase II study, ginger root extract decreased eicosanoids in colon mucosa in people at normal risk for colorectal cancer [39] . The present study shows that breast cancer cells are arrested in G 2 /M phase of the cell cycle after treatment with Results shown are mean ± SD (n = 3). Significantly different (P \ 0.05) compared with a respective DMSO-treated control and b between WT and DKO by one-way ANOVA followed by Bonferroni's multiple comparison test. Each experiment was done at least twice and representative data from one such experiment are shown ZER. While these observations are consistent with the literature data showing G 2 /M phase cell cycle arrest in ZERtreated leukemia, ovarian and cervical cancer cells [15, 25] , our data also indicates that the cell cycle arrest resulting from ZER exposure is irreversible. The G 2 /M progression is regulated by a kinase complex consisting of cyclin B1 and Cdk1 [40] and ZER treatment down regulates both these proteins. Downregulation of cyclin B1 and Cdk1 upon treatment with ZER has also been observed in leukemia cells [15] . The Cdc25 family phosphatases play an important role in activation of the cyclin B1/Cdk1 complex. The ZER-treated cells exhibit a decrease in protein levels of both Cdc25B and Cdc25C (present study). However, the cell cycle arrest resulting from ZER treatment is not dependent on p53, which is a therapeutic advantage because this tumor suppressor is often mutated in human cancers including breast cancer [41] . The present study indicates that PUMA protein, which is involved in regulation of apoptosis by different stimuli including some natural products [34, 42] , is dispensable for apoptosis induction by ZER. Likewise, unlike certain other proapoptotic agents [30], Bcl-2 overexpression has no meaningful impact on ZER-induced apoptosis. We also demonstrate that ZER causes activation of Bax and Bak but has only modest effect on their protein levels. Effect of ZER on Bak level or activation has not been examined previously to the best of our knowledge, but in leukemia cells ZER treatment had no effect on Bax protein expression [21] . A critical role for Bax in apoptosis induction by ZER has been reported in human colon cancer cells [24] . The ZER-induced apoptosis in colon cancer cells is associated with reactive oxygen species production [24] . Interestingly, examples exist to illustrate critical role of reactive oxygen species in Bax activation and apoptosis induction by some stimuli, including natural products phenethyl isothiocyanate (a constituent of watercress) and Withaferin A (a small molecule derived from a medicinal plant used in India) [43] [44] [45] . It is possible that Bax and Bak activation by ZER in breast cancer cells is linked to production of reactive oxygen species. Further work is needed to experimentally verify this possibility. 
